News from external sources

Jonas Einarsson and Elisabeth Kirkeng Andersen, from RADFORSK, are the two people behind the podcast Radium.

100 episodes of cancer research & development

From a relatively modest podcast to packed live shows at Arendalsuka, Radium has in three years grown into a leading cancer podcast in Norway.

Radium is a weekly podcast about Norwegian cutting-edge cancer research and development, produced by the evergreen investment fund Radforsk. Radforsk has 15 companies in its portfolio, of which five are on the stock market and 10 are also members of Oslo Cancer Cluster. Elisabeth Kirkeng Andersen, Communications Manager, and Jónas Einarsson, CEO of Radforsk, bring guests on the show to discuss recent development in the oncology field and news from the portfolio companies.

“Three years ago, Elisabeth came to me and said ‘Now, we are going to do something new – we will make a podcast’. I replied ‘That’s great! But what is a podcast?’” Einarsson said.

Andersen then took the first steps and employed students from the media program at Ullern Upper Secondary School to help with sound production.

 

Interested investors

Andersen and Einarsson quickly noticed there is great interest in the podcast, especially from investors and shareholders. They want to stay updated about Norwegian cancer research, a relatively new but growing sector. They often send in questions, which Andersen and Einarsson ask the guests in the studio.

“We try to simplify things. It is easier to hear it explained by someone from a company, than to read a difficult press release,” Andersen said.

“I think the best episodes are when we get a good dialogue with the CEOs of the companies, especially when things get a little heated. I try to lure them out on the thin ice to make them tell us more,” Einarsson said.

The popular podcast format has exploded in recent years, giving people access to accessible conversations that they can listen to whenever they want.

“There is no strict direction. We say that we are just going to have a conversation and then we talk for an hour or more,“ Einarsson said. “We have a down-to-earth style, but Elisabeth will pull us back if the guests or I dive too deep into details.”

 

Affecting health policies

Radium has also had several events with live streaming. At Arendalsuka this year, the premises were fully packed with eager listeners at both of their live shows.

“At Arendal, we try to have podcasts with others in the cancer field and aim to be more political. We think it has worked very well, because we can reach out to even more people when we stream the event,” Elisabeth said.

“I think the podcast will interest people working in the health industry and health politics too,” Einarsson said. “For example, the health minister was a guest for an entire hour, talking about current challenges.”

 

Best of Norwegian research

Radium regularly invites famous names from the Norwegian research community too. Steinar Aamdal, a prominent researcher in cancer immunotherapies has been a guest. Another cancer expert, Håvard Danielsen, who works on the DoMore project at Oslo University Hospital, has also talked on the podcast.

Øyvind Bruland and Roy Larsen, the serial entrepreneurs who started Algeta, Nordic Nanovector and OncoInvent, also visited the show.

Soon, Radium will host Kristian Berg, the researcher behind PCI Biotech’s technology: photochemical internalisation technology.

“I believe people think it is very interesting to, through the podcast, meet the people who actually have researched and developed the treatments,” Einarsson said.

 

For the patients

Einarsson and Andersen have also noticed that cancer patients or their family members listen to the podcast to hear about what is happening in the field.

“It is important to communicate that we do this for the patients. An important driving force is that we wish to contribute to developing better treatments for patients,” said Andersen.

“Every time the survival rate increases, it means one patient gets to live longer – and perhaps that is because of a treatment we have helped to develop,” said Einarsson. “To be a part of the journey with immunotherapy over the last 20 years, for an old doctor like me, is absolutely fantastic.”

 

Listen and download Radium:

 

Send in your ideas for guests and topics directly to Radium.

 

Episode 100 was recorded at Kulturhuset in Oslo, with several interesting guests, a friendly atmosphere and, delicious food and beverages. Stay tuned for upcoming live events via Radforsk’s Facebook page!

 

Sign up to OCC monthly newsletter

Torbjörn Furuseth, Targovax

New clinical trial at Oslo University Hospital

Our member Targovax has announced a new clinical trial for skin cancer patients at Oslo University Hospital.

The second part of a clinical trial for patients with refractory advanced melanoma (a type of skin cancer) will take place at Oslo University Hospital.

“We are excited that we can offer this treatment alternative to patients in our home country, and hopefully it will help us to recruit more patients faster,” said Torbjørn Furuseth, Chief Financial Officer, Targovax.

Targovax is a Norwegian biotech company that develops oncolytic viruses called ONCOS-102 to destroy cancer cells. The treatment is targeted towards solid tumours that are especially hard to treat. The ultimate goal is to activate the patient’s immune system to fight cancer.

Promising results

“The trial is until now conducted at three top hospitals in the US, where competition for patients to clinical trials is high. Oslo University Hospital is also a great cancer center, and currently there are no trials offered to this patient population,” said Furuseth.

Three out of nine patients responded to the treatment during the first part of the clinical trial. This included one complete response and two partial responses.

Dr. Magnus Jäderberg, CMO of Targovax, said: “It is promising to see this level of clinical responses after only three ONCOS-102 injections, including a complete response, which is rare in this heavily pre-treated patient population.”

A forceful combination

The treatment involves a combination of an oncolytic virus and an anti-PD1 checkpoint inhibitor.

The oncolytic virus is a modified virus that has been developed to selectively attack and kill cancer cells. You can read more about the oncolytic viruses on Targovax’s official website.

The anti-PD1 checkpoint inhibitor disrupts the interaction between proteins on the surface of cancer cells. This stops the cancer from evading the immune system.

“Earlier this year, we decided to expand the trial to test a more intensified schedule of ONCOS-102, and it will be interesting to see whether this regimen can generate more and deeper clinical responses,” said Dr. Alexander Shoushtari, Principal Investigator, Memorial Sloan Kettering Cancer Centre, New York.

The second part of the clinical trial is currently enrolling new patients.

 

Sign up to OCC newsletter

Sune Justesen and Stephan Thorgrimsen from Immunitrack

New tool to improve cancer vaccines receives funding

Oslo Cancer Cluster member Immunitrack has been awarded a grant from Eurostars to develop their prediction tool for cancer vaccines.

Immunitrack is a biotech company that develops software, which predicts immune responses and assesses new cancer vaccines.

Developing a new vaccine can be a lengthy and expensive process, with a high risk of failure. One key to success is being able to predict how the patient’s immune system will react, so drug developers can bring forth therapies that mobilize the immune system to fight the disease. Immunitrack’s tools can help developers predict the impact of a new drug on the patient’s immune system, before entering clinical trials.

Eurostars supports international innovative projects and is co-funded by Eureka member countries and the European Union Horizon 2020 framework programme. The funding will be used by Immunitrack over a 24-month period for the ImmuScreen Project, to develop a new prediction tool. It will both improve how cancer vaccines work and how to track patients’ immune responses.

“This Eurostar project will give additional momentum to the ongoing development of a best in class neo-epitope prediction tool, PrDx TM, by Immunitrack,” says Sune Justesen, CSO at Immunitrack.

Immunitrack will receive a total of approximately €750 000 from Eurostars, together with the Centre for Cancer Immune Therapy (CCIT), based in Herley, Denmark. CCIT aims to bridge the gap between research discovery and clinical implementation of treatments in the field of cancer immunotherapy.

“The collaboration with the Danish Cancer Center for Immune Therapy, is certainly an important step in validating and implementing PrDx, in the immune therapy treatment of cancer patients,” says Sune Justesen, CSO at Immunitrack.

Immunitrack will handle the software development, while CCIT performs the in vitro validation. The clinical validation will be carried out in melanoma patients. The results will help to characterize immune responses and help to understand why some tumours are immune to novel cancer vaccines.

 

Sign up to OCC monthly newsletter

Dr. Richard Stratford and Dr. Trevor Clancy, founders of OncoImmunity

Norwegian AI-based cancer research gets a boost

The Japanese tech giant NEC Corporation has acquired OncoImmunity AS, a Norwegian bioinformatics company that develops machine learning software to fight cancer.

This week, Oslo Cancer Cluster member OncoImmunity AS was bought by the Japanese IT and network company NEC Corporation. The company is now a subsidiary of NEC and operates under the name of NEC OncoImmunity AS. NEC has recently launched an artificial intelligence driven drug discovery business and stated in a press release that NEC OncoImmunity AS will be integral in developing NEC’s immunotherapy pipeline.

 

AI meets precision medicine

One of the great challenges when treating cancer today is to identify the right treatment for the right patient. Each cancer tumour is unique, and every patient has their own biological markers. So, how can doctors predict which therapy will work on which patient?

NEC OncoImmunity AS develops software to identify neoantigen targets for truly personalized cancer vaccines, cell therapies and optimal patient selection for cancer immunotherapy clinical trials. Neoantigen targets are parts of a protein that are unique to a patient’s specific tumor, and can be presented by the tumor to trigger the patient’s immune system to attack and potentially eradicate the tumor.

“The exciting field of personalized medicine is moving fast and becoming increasingly competitive. The synergy with NEC Corporation will allow us to make our technology even more accurate and competitive, as we can leverage NEC’s expertise in AI and software development and enable OI to deploy our technology on scale in the clinic due to their expertise in networks and cyber security,” said Dr. Trevor Clancy, Chief Scientific Officer and Co-founder.

“This acquisition gives us the opportunity to be a world leading player in this field and serve our Norwegian and international clients with improved and secure prediction technology in the medium to long term,” said Dr. Richard Stratford, Chief Executive Officer and Co-founder.

 

The rise to success

OncoImmunity was founded in 2014 and has been a member of Oslo Cancer Cluster since the early days of the start up. The co-founders Dr. Trevor Clancy and Dr. Richard Stratford said the cluster has been instrumental to their success and thanks the team for their advice and support from the very beginning of their journey:

“It is crucial with a technology like ours that we interact with commercial companies active in drug development, research, clinical projects, investors and other partners. Oslo Cancer Cluster is the perfect ecosystem in that regard as it provides the company with the networking and partnering opportunities that in effect support our science, technological and commercial developments.”

Mr. Anders Tuv, Investment Director of Radforsk, has been responsible for managing the sales process in relation to the Japanese group NEC Corporation on behalf of the shareholders. The shareholders are happy with the transaction and the value creation that was realised through it. Mr. Tuv commented:

“It is a huge recognition that such a global player as NEC sees the value of the product and expertise that have been developed in OncoImmunity AS and buys the company to strengthen their own investments in and development of AI-driven cancer treatment. It is also a recognition of what Norway is achieving in the field of cancer research, and it shows that Radforsk has what it takes to develop early-phase companies into significant global positions within the digital/AI-driven part of the industry. We believe that NEC will be a good owner going forward, and we wish the enterprise the very best in its future development.”

 

Medicine is becoming digital

NEC OncoImmunity AS is now positioned to become a front runner in the design of personalized immunotherapy driven by artificial intelligence. Dr. Trevor Clancy said that NEC and OncoImmunity share the common vision that medicine is becoming increasingly digital and that AI will play a key role in shaping future drug development:

“Both organizations believe strongly that personalized cancer immunotherapy will bring curative power to cancer patients, and this commitment from NEC is highlighted by the recent launch of their drug discovery business. The acquisition now means that both companies can execute on their vision and be a powerful force internationally to deliver true personalized medicine driven by AI.”

 

For more information, please visit the official websites of NEC Corporations and NEC OncoImmunity AS 

 

Sign up to OCC newsletter